MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Jan. 11, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) announced that Larry Jasinski, Chief Executive Officer, and Mike Lawless, Chief Financial Officer, will provide an overview presentation and host one-on-one meetings with investors at the Sidoti January Virtual Investor Conference, taking place on January 17-18, 2024.
The presentation will begin at 2:30 PM EST on January 17, 2024 and can be accessed live here. ReWalk will also host virtual one-on-ones with investors on Wednesday and Thursday, January 17-18, 2023. Registration is available to interested investors for the presentation or one-on-ones at www.sidoti.com/events. Registration is free and interested investors do not need to be a Sidoti client.
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. is a medical device company that designs, develops, and commercializes innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions. ReWalk’s mission is to fundamentally change the quality of life for these individuals through the creation and development of market leading technologies. Through its recent acquisition of AlterG, Inc., ReWalk has added anti-gravity systems to its growing portfolio of products. Founded in 2001, ReWalk has operations in the United States, Israel, and Germany. For more information on the ReWalk systems, please visit rewalk.com. For more information on the AlterG systems, please visit alterg.com.
ReWalk® and ReStore® are registered trademarks of ReWalk Robotics Ltd. in the United States and other jurisdictions. AlterG® is a registered trademark of AlterG, Inc. in the United States and other jurisdictions.
ReWalk Investor Contact:
Michael Lawless
Chief Financial Officer
ReWalk Robotics Ltd.
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
ReWalk Media Relations:
LifeSci Communications
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.50 |
| Daily Change: | 0.01 0.67 |
| Daily Volume: | 64,719 |
| Market Cap: | US$13.220M |
November 12, 2024 October 24, 2024 September 24, 2024 September 04, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
